Announced Mon, 29 Jun · 23:22 IST
Biocon makes Biocon Biologics wholly-owned subsidiary via share swap
Fund Raising View source PDF
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.9%1-day move
₹414.20
prior close
₹416.15
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.9-0.8-0.7-0.8+0.9+1.2+3.3+2.4-2.0-1.9+6.4———
Up moveDown movePending
AI summary
Biocon acquired 1.15 crore equity shares of Biocon Biologics Limited (BBL) from 127 selling shareholders in exchange for 87.86 lakh Biocon equity shares at about Rs 376.41 per share. This share swap makes BBL a wholly-owned subsidiary of Biocon. Shareholder approval was obtained via postal ballot on June 7, 2026. Paid-up equity capital rises from Rs 810.45 crore to Rs 814.85 crore. No cash outflow for the company.
Likely market impact
BBL becomes a wholly-owned subsidiary. Minor equity dilution around 0.5%. No cash outflow for Biocon.